Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure

Overview

This is a multicenter, prospective, randomized controlled study for the purpose of comparing DERMABOND PROTAPE to DERMABOND HVD for closure of wounds in the Emergency Department. The objective of this study is to demonstrate whether the incidence of wound closure for DERMABOND PROTAPE is equivalent to that measured for DERMABOND HVD.

Full Title of Study: “Multicenter, Prospective, Randomized Controlled Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Closure of Simple, Thoroughly Cleansed, Trauma-induced Wounds in the Emergency Department”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2009

Detailed Description

According to the literature, cyanoacrylate adhesives (topical skin adhesive) have performed as intended and have not produced results that would bring into question the safety or effectiveness of cyanoacrylate adhesive for closure of surgical incisions and traumatic wounds in humans. As such, this is a multicenter, prospective, randomized controlled study for the purpose of comparing two forms of topical skin adhesives, DERMABOND PROTAPE & DERMABOND HVD for closure of wounds in the Emergency Department. Patients presenting in the Emergency Department with traumatic wounds meeting the acceptance criteria will have their wounds closed with DERMABOND PROTAPE or DERMABOND HVD, and will be monitored and evaluated at 14 & 30 days.

Interventions

  • Device: cyanoacrylate with pressure sensitive mesh
    • Topical Skin Adhesive
  • Device: cyanoacrylate
    • Topical Skin Adhesive

Arms, Groups and Cohorts

  • Experimental: Dermabond Protape
    • DERMABOND PROTAPE (Prineo) Topical Skin Adhesive
  • Active Comparator: Dermabond HVD
    • DERMABOND HVD Topical Skin Adhesive

Clinical Trial Outcome Measures

Primary Measures

  • The Incidence of Wound Closure Post-treatment, as Defined by Continuous Approximation of Wound Margins From the Time of Wound Closure Until the Day of Evaluation Without Dehiscence or Need for Reclosure.
    • Time Frame: 14 days (±2 days)
    • Data is presented as binomial tables of proportions of successes and failures for each treatment. The 90% two-sided exact confidence intervals (CI) for the differences in the proportions for each study group was calculated. The upper limit of the 90% CI was then taken to represent the upper limit of the one-sided 95% CI. The primary objective of the study was met if the upper limit of the one-sided 95% CI of the difference in proportions (comparator minus treatment) did not exceed 8%.

Secondary Measures

  • Cosmesis
    • Time Frame: 30 days (±5 days)
    • The evaluation of healing and cosmetic outcome post-treatment using the modified Hollander Cosmesis Scale (mHCS). The proportion of patients with a zero (0) score will be compared between the test and control arms.

Participating in This Clinical Trial

Inclusion Criteria

  • at least 1 year of age – in good general health in the opinion of the Investigator. – have at least one traumatic wound meeting the criteria for closure as defined in current Dermabond product labeling. – patient must be willing to follow instructions for wound care listed in device labeling and refrain from picking at the device, applying topical medications to the wound, and swimming or soaking in a tub until the sutures are removed. – patient agrees to return for follow-up evaluation – patient (or guardian) signs the informed consent – patient is reasonably expected to survive the study Exclusion Criteria:

  • significant multiple trauma (merely multiple wounds are allowed) – peripheral vascular disease – insulin dependent diabetes mellitus – known to have a blood clotting disorder – receiving antibiotic therapy for preexisting condition or infection – known to be HIV-positive or otherwise immunocompromised – known personal or family history of keloid formation or hypertrophy – currently taking systemic steroids – known allergy to cyanoacrylate, formaldehyde, tapes or adhesives – participating in another current clinical study – history of abnormal wound healing – burst stellate lacerations due to a crush or hard blow – animal or human bite or scratch – decubitus ulcer – puncture wound – wound at mucocutaneous junction or in mucosal (but not excluding the vermillion border of the lip) – wound on scalp covered by natural hair – wound has visual evidence of active infection – gangrenous wound – wound requiring debridement of devitalized or contaminated tissue – wound at site of active rash/skin lesion making evaluation difficult – previously treated wound or has failed to heal – wound in high skin tension area or across an area of increased skin tension, such as knuckles, elbows, or knees, unless the joint will be immobilized during the skin healing period or unless skin tension has been removed by application

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ethicon, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Helen Colquhoun, MD, Study Director, Pleiad Devices

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.